Company
Newsroom.
Our press releases provide you with detailed information about Ottobock's products, social responsibility and global presence. Learn about the latest technologies and current highlights in the medical technology sector. As a company that conducts research, we feature numerous interesting topics.
Press releases.
Thursday, 19 March 2026
Ottobock publishes Annual Report 2025 | Preliminary figures confirmed | Dividend proposal of € 0.97 per share
Record result with double-digit growth
• Core revenues¹ up 11.7 percent to € 1.6 billion
• Underlying core EBITDA grows by 29.5 percent to € 415.3 million; underling core EBITDA margin reaches 26.0 percent
• Underlying net income rises by 83.2 percent to € 177.3 million
• Proposed dividend of € 0.97 per share confirms strategic payout ratio of 30–40 percent of underlying net income
Record result with double-digit growth
• Core revenues¹ up 11.7 percent to € 1.6 billion
• Underlying core EBITDA grows by 29.5 percent to € 415.3 million; underling core EBITDA margin reaches 26.0 percent
• Underlying net income rises by 83.2 percent to € 177.3 million
• Proposed dividend of € 0.97 per share confirms strategic payout ratio of 30–40 percent of underlying net income
Monday, 16 March 2026
Repairs, Medals and Short Tights: A Technical Service That Moves the Paralympic Winter Games.
With more than 490 repairs, Ottobock supported the athletes at the Milano Cortina 2026 Paralympic Winter Games.
With more than 490 repairs, Ottobock supported the athletes at the Milano Cortina 2026 Paralympic Winter Games.
Saturday, 7 March 2026
Three Locations, One Team: Ottobock Opens Workshops at the Milano Cortina 2026 Paralympic Winter Games.
Repair services successfully launched in Milan, Cortina and Predazzo – virtual Tour for Journalists
Repair services successfully launched in Milan, Cortina and Predazzo – virtual Tour for Journalists
Thursday, 26 February 2026
Ottobock invests in future technology from Blue Arbor Technologies, Inc.
The international MedTech company is driving progress in intuitive prosthesis control.
• Investment of USD 5 million in Series A financing.
• RESTORE implant technology provides more intuitive prosthesis control.
• First test treatment successfully carried out at the Medical University of Vienna.
The international MedTech company is driving progress in intuitive prosthesis control.
• Investment of USD 5 million in Series A financing.
• RESTORE implant technology provides more intuitive prosthesis control.
• First test treatment successfully carried out at the Medical University of Vienna.
5 results out of 304